格隆汇11月20日丨特宝生物(688278.SH)在投资者互动平台表示，目前公司主营业务产品以内销为主， 海外销售收入占比较小，且出口国家不涉及欧盟。 ...

Core Viewpoint - Guangge Technology reported a significant revenue increase of 71.44% year-on-year, reaching 87.38 million yuan in the first half of the year, primarily due to the completion of delayed projects from the previous year [1] Financial Performance - Revenue for the first half of the year was 87,380,277.47 yuan, compared to 50,969,136.17 yuan in the same period last year, marking a 71.44% increase [1] - The total profit for the period was a loss of 31,390,744.96 yuan, compared to a loss of 28,312,079.73 yuan in the previous year, indicating a worsening financial situation [1] - The net profit attributable to shareholders was a loss of 31,377,466.92 yuan, compared to a loss of 20,165,730.04 yuan in the same period last year [1] - The net cash flow from operating activities was -26,468,194.41 yuan, an improvement from -45,892,865.97 yuan in the previous year [1] Earnings Per Share - Basic earnings per share for the first half of the year was -0.48 yuan, compared to -0.31 yuan in the same period last year [2] - Diluted earnings per share also stood at -0.48 yuan, reflecting the same trend as basic earnings [2] - The basic earnings per share after deducting non-recurring gains and losses was -0.52 yuan, compared to -0.34 yuan in the previous year [2] Profitability and Costs - The gross margin of the main business products decreased, leading to an increase in main business costs compared to the previous year [2] - The company has been expanding into new products and industries, which has resulted in increased research and development expenses, contributing to higher period costs [2] - The weighted average return on equity decreased to -3.15%, down 1.29 percentage points from the previous year [2]